Cognition Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Cognition Therapeutics (CGTX) received a notice from Nasdaq on November 3, 2026, for failing to maintain a minimum closing bid price of $1.00 for 30 consecutive days. The company has until May 3, 2027, to comply with the listing rule. Its stock continues to trade on the Nasdaq Capital Market without immediate impact.
How this was made
The 30-second read
Why it matters
The listing deficiency highlights liquidity concerns and may trigger share sell‑offs.
Market read
The notice could pressure CGTX shares lower until compliance is restored.
What to watch
Potential upcoming financing or reverse split could mitigate delisting risk.
Background
Cognition Therapeutics is a clinical‑stage biotech listed on Nasdaq Capital Market.
Ticker impact
Nasdaq notified Cognition Therapeutics (CGTX) that its closing bid price stayed below $1.00 for 30 consecutive days, triggering a listing rule violation.
likely pressure as investors price in potential delisting risk
A bid price below $1 for an extended period signals liquidity weakness and may trigger a forced delisting if not remedied.
Market effects
May raise scrutiny on other micro‑cap biotech stocks trading near $1.
Limited to U.S. Nasdaq micro‑caps.
Minimal global impact.
Counterpoint
If CGTX can raise its price above $1 quickly, the notice could be a short‑term catalyst for a bounce.
Key entities
- Regulatory BodyNasdaq
Issuer of the listing rule violation notice.
- CompanyCognition Therapeutics Inc.
Subject of the compliance notice.
